Human uPAR Quantikine ELISA Kit

• Reactivity: Hu
• Applications: ELISA
• Conjugate: HRP

Human uPAR Quantikine ELISA Kit Summary

• Background: The Quantikine Human uPAR Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human uPAR in cell culture supernates, serum, plasma, and urine. It contains NS0-expressed recombinant human uPAR and antibodies raised against the recombinant factor. It has been shown to accurately quantitate the recombinant factor. Results obtained using natural human uPAR showed linear curves that w...ere parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values of natural human uPAR.
  Show More
• Specificity: Natural and recombinant human uPAR
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: PLAUR

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: Interference observed with 1 or more available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human uPAR Quantikine ELISA Kit

• CD87 antigen
• CD87
• Monocyte activation antigen Mo3
• plasminogen activator, urokinase receptor
• PLAUR
• uPAR
• U-PAR
• UPARurokinase plasminogen activator surface receptor
• u-plasminogen activator receptor form 2
• URKRMO3

Background

The urokinase-type Plasminogen Activator Receptor (uPAR) is a GPI-anchored protein that binds to both the inactive and active forms of uPA. This interaction serves to localize and enhance the proteolytic activity of uPA, leading to increased conversion of Plasminogen to Plasmin. uPA also triggers uPAR-mediated signal transduction, activation of protein tyrosine kinases, gene expression, cell adhesion, and chemotaxis. uPAR can additionally regulate cell adhesion by direct binding to Vitronectin and preventing Integrins from binding to their ligands.

⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Publications for uPAR (DUP00)(43)

Publications using DUP00

• GH Brody, T Yu, GE Miller, E Chen Longitudinal links between early adolescent temperament and inflammation among young black adults Psychoneuroendocrinology, 2023-03-06;152(0):106077. 2023-03-06 [PMID: 36931166] (Human)
• J Joyce, N Cabanas, R Pisharody, B Ouyang, R Patel, J Reiser, DA Hall, N Witek Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism Parkinsonism & related disorders, 2022-06-28;101(0):39-42. 2022-06-28 [PMID: 35780693] (Human)
• MA Hladunewic, D Cattran, SM Sethi, SS Hayek, J Li, C Wei, SI Mullin, HN Reich, J Reiser, FC Fervenza Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte beta3 Integrin Kidney international reports, 2021-10-30;7(1):68-77. 2021-10-30 [PMID: 35005315] (Human)
• GE Miller, E Chen, E Finegood, D Shimbo, SW Cole Prospective associations between neighborhood violence and monocyte pro-inflammatory transcriptional activity in children Brain, Behavior, and Immunity, 2021-11-17;100(0):1-7. 2021-11-17 [PMID: 34800620] (Human)
• S Buhelt, HB Søndergaar, MR Mahler, S Cobanovic, L Börnsen, C Ammitzbøll, AB Oturai, F Sellebjerg Biomarkers of systemic inflammation, soluble IL-2Ralpha and the multiple sclerosis-associated IL2RA SNP rs2104286 in healthy subjects and multiple sclerosis patients Multiple sclerosis and related disorders, 2021-07-07;54(0):103140. 2021-07-07 [PMID: 34304016] (Human)
• A Olsson, S Gustavsen, AR Langkilde, TH Hansen, F Sellebjerg, H Bach Sønde, AB Oturai Circulating levels of tight junction proteins in multiple sclerosis: Association with inflammation and disease activity before and after disease modifying therapy Multiple sclerosis and related disorders, 2021-07-03;54(0):103136. 2021-07-03 [PMID: 34247104] (Human)
• X Li, D Qi, MY Wang, K Ji, QL Xie, Y Wang, SH Du, HY Fan Salvianolic acid A attenuates steroid resistant nephrotic syndrome through suPAR/uPAR-&alphav&beta3 signaling Inhibition Journal of ethnopharmacology, 2021-06-19;279(0):114351. 2021-06-19 [PMID: 34157324] (Human)
• U Jehn, K Schütte-Nü, U Henke, H Pavenstädt, B Suwelack, S Reuter Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients Scientific Reports, 2021-02-12;11(1):3713. 2021-02-12 [PMID: 33580120] (Human)
• A Olsson, S Gustavsen, IC Hasselbalc, AR Langkilde, F Sellebjerg, AB Oturai, HB Søndergaar Biomarkers of inflammation and epithelial barrier function in multiple sclerosis Mult Scler Relat Disord, 2020-09-19;46(0):102520. 2020-09-19 [PMID: 32980645] (Human)
• J Wajda, P Dumnicka, W Kolber, M Sporek, B Maziarz, P Ceranowicz, M Ku?niewski, B Ku?nierz-C The Marker of Tubular Injury, Kidney Injury Molecule-1 (KIM-1), in Acute Kidney Injury Complicating Acute Pancreatitis: A Preliminary Study J Clin Med, 2020-05-13;9(5):. 2020-05-13 [PMID: 32414176] (Human)
• F Huang, Y Li, R Xu, A Cheng, Y Lv, Q Liu The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis Mediators Inflamm., 2020-04-07;2020(0):7850179. 2020-04-07 [PMID: 32322165] (Human)
• JN An, JS Hyeon, Y Jung, YW Choi, JH Kim, SH Yang, S Oh, S Kwon, SH Lee, JH Cho, SH Park, H Ha, DK Kim, JP Lee, GS Hwang Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis Sci Rep, 2019-10-11;9(1):14707. 2019-10-11 [PMID: 31605028] (Human)
• W Winnicki, G Sunder-Pla, G Sengölge, A Handisurya, H Herkner, C Kornauth, B Bielesz, L Wagner, Ž Kiki?, S Pajenda, T Reiter, B Schairer, A Schmidt Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method Sci Rep, 2019-09-24;9(1):13783. 2019-09-24 [PMID: 31551522] (Human)
• K Kikuchi, D Saigusa, Y Kanemitsu, Y Matsumoto, P Thanai, N Suzuki, K Mise, H Yamaguchi, T Nakamura, K Asaji, C Mukawa, H Tsukamoto, T Sato, Y Oikawa, T Iwasaki, Y Oe, T Tsukimi, NN Fukuda, HJ Ho, F Nanto-Hara, J Ogura, R Saito, S Nagao, Y Ohsaki, S Shimada, T Suzuki, T Toyohara, E Mishima, H Shima, Y Akiyama, Y Akiyama, M Ichijo, T Matsuhashi, A Matsuo, Y Ogata, CC Yang, C Suzuki, MC Breeggeman, J Heymann, M Shimizu, S Ogawa, N Takahashi, T Suzuki, Y Owada, S Kure, N Mano, T Soga, T Wada, JB Kopp, S Fukuda, A Hozawa, M Yamamoto, S Ito, J Wada, Y Tomioka, T Abe Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease Nat Commun, 2019-04-23;10(1):1835. 2019-04-23 [PMID: 31015435] (Human)
• L Beckert, B Brockway, G Simpson, AM Southcott, YCG Lee, N Rahman, RW Light, S Shoemaker, J Gillies, AA Komissarov, G Florova, T Ochran, W Bradley, H Ndetan, KP Singh, K Sarva, S Idell Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema JCI Insight, 2019-04-18;5(0):. 2019-04-18 [PMID: 30998508] (Human)
• S Shuster, G Ankawi, C Licht, J Reiser, X Wang, C Wei, D Chitayat, M Hladunewic Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR J Clin Med, 2018-10-04;7(10):. 2018-10-04 [PMID: 30287750] (Human)
• W Kolber, B Ku?nierz-C, P Dumnicka, M Maraj, M Mazur-Lask, M P?dziwiatr, P Ceranowicz Serum Urokinase-Type Plasminogen Activator Receptor Does Not Outperform C-Reactive Protein and Procalcitonin as an Early Marker of Severity of Acute Pancreatitis J Clin Med, 2018-09-27;7(10):. 2018-09-27 [PMID: 30262764] (Human)
• C Torino, P Pizzini, S Cutrupi, M Postorino, G Tripepi, F Mallamaci, J Reiser, C Zoccali Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients Kidney Int Rep, 2018-05-22;3(5):1100-1109. 2018-05-22 [PMID: 30197976] (Human)
• J Zhou, KJ Kwak, Z Wu, D Yang, J Li, M Chang, Y Song, H Zeng, LJ Lee, J Hu, C Bai PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway Cell. Physiol. Biochem., 2018-06-29;47(5):1909-1924. 2018-06-29 [PMID: 29961070] (Human)
• W Wu, Y Cui, J Hu, R Liao, S Li, L Mo, L Xu, Y Chen, Z Lian, X Tian, Z Li, R Li, L Zhang, H Liang, J Ma, T Lin, Z Feng, W Dong, G Ke, P Ge, Z Ye, W Wang, B Zhang, W Shi, X Liang, S Liu Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis Kidney Blood Press. Res., 2018-05-03;43(3):664-672. 2018-05-03 [PMID: 29734173] (Human)
• SS Hayek, J Divers, M Raad, J Xu, DW Bowden, M Tracy, J Reiser, BI Freedman Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein J Am Heart Assoc, 2018-05-01;7(9):. 2018-05-01 [PMID: 29716888] (Human)
• Q Luo, P Ning, Y Zheng, Y Shang, B Zhou, Z Gao Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study Crit Care, 2018-01-24;22(1):15. 2018-01-24 [PMID: 29368632] (Human)
• AS Koh, B Velmurugan, F Gao, RS Tan, JI Wong, LLY Teo, BMH Keng, SJM Chua, JM Yuan, WP Koh, C Cheung Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation BMC Geriatr, 2017-11-28;17(1):275. 2017-11-28 [PMID: 29179674] (Human)
• M Guthoff, R Wagner, E Randrianar, E Hatziagela, A Peter, HU Häring, A Fritsche, N Heyne Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus Sci Rep, 2017-01-16;7(0):40627. 2017-01-16 [PMID: 28091558] (Human)
• Guo S, Han M, Chen M, Ning Y, Pei G, Li Y, Dai W, Ge S, Deng Y, Guo Y, Li X, Haller H, Xu G, Rong S Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China. PLoS ONE, 2015-09-18;10(9):e0138718. 2015-09-18 [PMID: 26380984] (Human)
• Zhao Y, Liu L, Huang J, Shi S, Lv J, Liu G, Zhao M, Zhang H Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy. PLoS ONE, 2015-07-13;10(7):e0132869. 2015-07-13 [PMID: 26167688] (Human)
• Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piche A Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer, 2015-07-01;15(0):492. 2015-07-01 [PMID: 26122176] (Human)
• Gilder A, Jones K, Hu J, Wang L, Chen C, Carter B, Gonias S Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion. J Biol Chem, 2015-04-02;290(24):14798-809. 2015-04-02 [PMID: 25837250] (Human)
• Chang M, Chang H, Chan C, Yeung S, Hsien H, Lin B, Yeh C, Tseng W, Tseng S, Jeng J p-Cresol affects reactive oxygen species generation, cell cycle arrest, cytotoxicity and inflammation/atherosclerosis-related modulators production in endothelial cells and mononuclear cells. PLoS ONE, 2014-12-17;9(12):e114446. 2014-12-17 [PMID: 25517907] (Human)
• Spinale J, Mariani L, Kapoor S, Zhang J, Weyant R, Song P, Wong H, Troost J, Gadegbeku C, Gipson D, Kretzler M, Nihalani D, Holzman L A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int, 2014-10-29;87(3):564-74. 2014-10-29 [PMID: 25354239] (Human)
• Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, Naesens M, Storr M, Kuypers D, Evenepoel P Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int, 2014-06-04;87(1):210-6. 2014-06-04 [PMID: 24897037] (Human)
• Huang J, Liu G, Zhang Y, Cui Z, Wang F, Liu X, Chu R, Zhao M Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med, 2014-05-20;12(0):81. 2014-05-20 [PMID: 24884842] (Human)
• Sinha , Aditi, Bajpai , Jaya, Saini , Savita, Bhatia , Divya, Gupta , Aarti, Puraswani , Mamta, Dinda , Amit K, Agarwal , Sanjay K, Sopory , Shailaja, Pandey , Ravindra, Hari , Pankaj, Bagga , Arvind Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int, 2014-01-15;85(3):649-58. 2014-01-15 [PMID: 24429405] (Human)
• Maas RJ, Wetzels JF, Deegens JK Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int., 2012-05-01;81(10):1043-4. 2012-05-01 [PMID: 22543906] (Human)
• Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med., 2011-07-31;17(8):952-60. 2011-07-31 [PMID: 21804539] (Human)
• Zuckerman ST, Brown JF, Kao WJ Identification of regulatory Hck and PAI-2 proteins in the monocyte response to PEG-containing matrices. Biomaterials, 2009-05-14;30(23):3825-33. 2009-05-14 [PMID: 19443025] (Human)
• Beaufort N, Leduc D, Eguchi H, Mengele K, Hellmann D, Masegi T, Kamimura T, Yasuoka S, Fend F, Chignard M, Pidard D The human airway trypsin-like protease modulates the urokinase receptor (uPAR, CD87) structure and functions. Am. J. Physiol. Lung Cell Mol. Physiol., 2007-01-19;292(5):L1263-72. 2007-01-19 [PMID: 17237151] (Human)
• Brooks AM, Bates ME, Vrtis RF, Jarjour NN, Bertics PJ, Sedgwick JB Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma. Am. J. Respir. Cell Mol. Biol., 2006-05-25;35(4):503-11. 2006-05-25 [PMID: 16728704] (Human)
• Lash GE, Otun HA, Innes BA, Bulmer JN, Searle RF, Robson SC Low oxygen concentrations inhibit trophoblast cell invasion from early gestation placental explants via alterations in levels of the urokinase plasminogen activator system. Biol. Reprod., 2005-10-26;74(2):403-9. 2005-10-26 [PMID: 16251495] (Human)
• Wang J, Stockton DW, Ittmann M The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin. Cancer Res., 2004-09-15;10(18):6169-78. 2004-09-15 [PMID: 15448004] (Human)
• Cobos E, Jumper C, Lox C Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer. Clin. Appl. Thromb. Hemost., 2003-07-01;9(3):241-6. 2003-07-01 [PMID: 14507113] (Human)
• Rigolin GM, Tieghi A, Ciccone M, Bragotti LZ, Cavazzini F, Della Porta M, Castagnari B, Carroccia R, Guerra G, Cuneo A, Castoldi G Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. Br. J. Haematol., 2003-03-01;120(6):953-9. 2003-03-01 [PMID: 12648064] (Human)
• Jumper C, 107301, Cobos E, Lox C The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC). Highly sensitive quantification of bacterial chondroitin in a culture based on ELISA techniques, 2002-07-01;22(4):2073-6. 2002-07-01 [PMID: 12174885] (Human)

Bioinformatics

• Gene Symbol: PLAUR